After two flops, Roche and Exelixis post early PhIII win for Tecentriq/Cabometyx combo — but will wait for OS data
Roche and Exelixis have finally notched a Phase III win with the combination of Tecentriq and Cabometyx, clearing the progression-free survival bar in metastatic castration-resistant prostate cancer.
The companies — along with ex-US partners at Ipsen and Takeda — have had little success with the drug combination in solid tumors. Out of three pivotal trials, Tecentriq plus Cabometyx already failed two, namely CONTACT-01 in non-small cell lung cancer and CONTACT-03 in renal cell carcinoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.